Skip to main content
Clinical Trials/CTRI/2025/05/086180
CTRI/2025/05/086180Not yet recruitingNot Applicable

A Comparative Clinical Study To Evaluate The Effect Of Marichanjana And Darvadyanjana In The Management Of Arma With Special Reference to Pterygium

Dr Divya Tukaram Moodi1 site in 1 country40 target enrollmentStarted: May 5, 2025Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
40
Locations
1
Primary Endpoint
2 Length

Study Overview

Brief Summary

Armais one among Shuklagataroga explained by Acharya Sushrutha and Acharya Vagbhata. It is defined as IYARTI GACCHATHI ITI ARMA. Which means gradually spreading of fleshy growth occurring in Shukla mandala. The Lakshanas of Arma can be correlated with signs and symptoms of Pterygium in modern ophthalmology. Pterygium is a wing shaped fold of conjunctiva encroaching upon cornea from either side within interpalpebral fissure. Pathologically Pterygium is an elastotic degeneration of subconjunctival tissue. In a population-based study from rural central India, prevalence of pterygium increased from 6.7±0.8% in the age group from 30–39 years to 25.3±2.1% in the age group of 70–79 years. The epidemiological studies around worldwide have shown that prevalence rates ranges from 0.3% to 37.46%.

Pterygium is more common in people living in hot climate, and in those who work outdoors. Thus it is considered as a response to prolonged effect of environmental factors such as exposure to sunlight (UV rays), dry heat, high wind and abundance of dust. Asymptomatic nature of the disease and non-availability of medical treatment are the main hurdles in management. Meanwhile it fails to decrease the complication such as development of cyst, ongoing diplopia, Dry eye, scleral or corneal melting. it not only affects the outlook of the patient, but also affects refractive astigmatism which can have significant impact on vision in advanced stage due to the invasion of cornea.

In modern science surgical treatment is only satisfactory approach. Recurrence after surgical excision is common and recurred lesions grow more aggressively than primary lesions. Cost of Surgery is too expensive. Hence to overcome the lacuna in modern therapeutics the present clinical study has been taken up. Therefore an alternative treatment which is safe, devoid of complication, easy to administer and cost effective is need for hour.

In Classics different treatment modalities are explained for the management of Arma mainly Lekhana, Chedhana, Anjana. Arma is a type of Mamsavriddhi (muscle like growth) hence Acharyas have indicated as Chedana sadya and Lekhana sadya vyadhi. Marichanjanaand Darvadyanjanaboth are mentioned in Basavarajeeyam, Netraroghadhikara. Hence an attempt is made to compare the efficacy of Marichanjana and Darvadyanjana in management of ARMA

NULL HYPOTHESIS

H0 - Marichanjana is not effective in management of Arma with special reference to   pterygium.

ALTERNATE HYPOTHESIS

H1 - Marichanjana Is more effective than Darvadyanjana i in management Arma with special reference to pterygium

H2 - Marichanjana is less effective than Darvadyanjana in management of Arma with special reference to pterygium.

Study Design

Study Type
Interventional
Allocation
Coin toss, Lottery, toss of dice, shuffling cards etc
Masking
Open Label

Eligibility Criteria

Ages
30.00 Year(s) to 70.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • •1 Patients between age group of 30 years to 70 years.
  • •2 Clinical features as per classics.
  • •3 Patients with Pterygium that is limited to limbus.
  • •4 Controlled Diabetic patients 5 Controlled HTN Patients.

Exclusion Criteria

  • •1 Arma with any other ocular pathology.
  • •2 Pseudo pterygium 3 Those contraindicated for Anjana karma.
  • •4 Pregnant women and Lactating mother.

Outcomes

Primary Outcomes

2 Length

Time Frame: 60 Days

1 Pictorial presentation

Time Frame: 60 Days

3 Thickness

Time Frame: 60 Days

Secondary Outcomes

  • 1 Foriegn body sensation(2 Redness)

Investigators

Sponsor
Dr Divya Tukaram Moodi
Sponsor Class
Other [self]

Study Sites (1)

Loading locations...

Similar Trials